Skip to main content
SpringerLink
Log in

Tumor therapy of neoplastic diseases with tumor cells and neuraminidase

Further experimental studies on chessboard vaccination in canine mammary tumors

  • Original Articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

The therapeutic effect of i. d. injection of tumor cells mixed with Vibrio cholerae neuraminidase (VCN) on tumor progression in dogs with spontaneous mammary tumors was investigated. The i. d. injections were performed in a chessboard-like manner: different numbers (105, 106, 107, and 108) of mitomycin-treated autologous tumor cells (M-TC) were each mixed with different amounts (10, 50, and 100 mU) of VCN. These different mixtures were injected i. d. at different sites in dogs on the day of resection of a part of multiple tumors.

In a randomized prospective study in 71 dogs the effect of chessboard vaccination (autologous tumor cells and VCN) on the growth of the residual tumor mass was compared to chessboard-like treatments with mixtures of either autologous erythrocytes and VCN or autologous tumor cells and heat-inactivated VCN.

The results show that:

  • chessboard vaccination induced regression (6 of 23) of spontaneous mammary tumors in dogs. No dog died as a result of the tumor within an observation period of 1 year. The therapeutic effect of chessboard vaccination was dependent on the application of tumor cells and enzymatically active VCN. In contrast, control treatment with either heat-inactivated VCN or autologous erythrocytes instead of tumor cells did not induce any regressions. Some animals in both control groups died because of tumor growth (3/21 and 2/27 respectively).

  • The delayed type hypersensitivity (DTH) response of tumor-bearing animals against i. d. applied tumor cells was not significantly enhanced by the admixture of enzymatically active VCN, nor did the DTH response seem to be predictive of a therapeutic effect on the tumor. No difference in the DTH response of dogs to autologous tumor cells mixed with active or inactivated VCN or autologous erythrocytes mixed with active VCN could be found.

  • Thomsen-Friedenreich antigens were serologically detected on canine erythrocytes after treatment with VCN and on untreated cells of mammary tumors from dogs. Exposure of Thomsen-Friedenreich antigens after treatment with VCN was enhanced on canine mammary tumors. As chessboard vaccination proved to be unsuccessful when canine autologous erythrocytes were used instead of autologous tumor cells, it can be concluded that the exposure of Thomsen-Friedenreich antigen plays no decisive role in tumor therapy with tumor cells and VCN.

  • Chessboard vaccination was tolerated without any side effects. Tumor enhancement was never observed.

Chessboard vaccination appears to be an effective and safe procedure for tumor therapy using tumor cells and VCN. The mechanism underlying the therapeutic effect of chessboard vaccination is completely unknown.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bekesi JG, Holland JF (1975) Chemoimmunotherapy of leukemia in man and experimental animals. International conference on immunotherapy of cancer, Nov 5–7, New York

  2. Bekesi JG, Holland JF (1977) Active immunotherapy in leukemia with neuraminidase-modified leukemic cells. Recent Results Cancer Res 62:78

    Google Scholar 

  3. Bekesi JG, St-Arneault G, Holland JF (1971) Increase of leukemia L-1210 immunogenicity by Vibrio cholerae neuraminidase treatment. Cancer Res 31:2130

    Google Scholar 

  4. Bekesi JG, St-Arneault G, Walter L, Holland JF (1972) Immunogenicity of leukemia L-1210 cells after neuraminidase treatment. J Natl Cancer Inst 49:107

    Google Scholar 

  5. Bekesi JG, Roboz JP, Walter L, Holland JF (1974) Stimulation of specific immunity against cancer by neuraminidase-treated tumor cells. Behring Inst Mitt 55:309

    Google Scholar 

  6. Bekesi JG, Holland JF, Cuttner J, Silver R, Colman M (1982) Immunotherapy of acute myelocytic leukemia with neuraminidase modified myeloblasts as immunogen. Proc Am Soc Clin Oncol 1, Waverly Press, London, p 36

    Google Scholar 

  7. Bostock DE, Gorman NT (1978) Intravenous BCG therapy of mammary carcinoma in bitches after surgical excision of the primary tumor. Eur J Cancer 14:879

    Google Scholar 

  8. Brecher J, Schneiderman M, Cronkite EP (1953) The reproducibility and constancy of the platelet count. Am J Clin Pathol 23:15

    Google Scholar 

  9. Comb DG, Roseman S (1962) N-acetylneuraminic acid aldolase: In: Methods in enzymology, 5. Academic Press, New York, p 391

    Google Scholar 

  10. Deems RA, Eaon BR, Dennis EA (1975) Kinetic analysis of phospholipase A2 activity toward mixed micelles and its implications for the study of lipolytic enzymes. J Biol Chem 250:9013

    Google Scholar 

  11. Dorn CR, Taylor DON, Frye FL, Hibbard HH (1968) Survey of animal neoplasms in Alameda and contra costa counties, California. I. Methodology and description of cases. J Natl Cancer Inst 40:295

    Google Scholar 

  12. Erlanger BF, Kokowsky N, Cohen W (1961) The preparation and properties of two new chromogenic substrates of trypsin. Arch Biochem Biophys 95:271

    Google Scholar 

  13. Fidler IJ, Brodeys RS, Bech-Nielsen S (1974) In vitro immune stimulation-inhibition to spontaneous canine tumors of various histologic types. J Immunol 112:1051

    Google Scholar 

  14. Hannant D, Else RW, Crighton GW (1978) Antigens associated with canine spontaneous mammary carcinoma. Vet Rec 103:441

    Google Scholar 

  15. Hannant D, Else RW, Crighton GW (1979) Antigenic enhancement of canine mammary tumors by autoimmunisation with DNP-conjugates. Vet Rec 104:350

    Google Scholar 

  16. Holland JF, Bekesi JG (1979) Comparison of chemotherapy with chemotherapy plus VCN-treated cells in acute myelocytic leukemia: In: Immunotherapy of cancer: present status of trials in man. Raven Press, New York, p 347

    Google Scholar 

  17. Hughes RC, Palmer PD, Sanford BH (1973) Factors involved in the cytotoxicity of normal guinea-pig serum for cells of murine tumor TA3 sublines treated with neuraminidase. J Immunol 111:107

    Google Scholar 

  18. Johanssen R, Sedlacek HH, Seiler FR (1978) Adjuvant effect of Vibrio cholerae neuraminidase on the in vitro and in vivo immune response: In: Proceedings of the Symposium “Immunotherapy of malignant diseases”. Schattauer, Stuttgart, p 244

    Google Scholar 

  19. Johannsen R, Sedlacek HH, Seiler FR (1979) The neuraminidase-induced enhanced immune response can be attributed to immune stimulatory and antigenic properties of the enzyme. Transplant Proc. 11:1411

    Google Scholar 

  20. Klein PG, Newman RA, Müller P, Uhlenbruck G, Schaefer HE, Lennartz KJ, Fischer R (1978) Histochemical methods for the demonstration of Thomsen-Friedenreich antigen in cell suspensions and tissue section. Klin Wschr 56:761

    Google Scholar 

  21. Knop J (1980) Effect of Vibrio cholerae neuraminidase on the mitogen response of T-lymphocytes. I. Enhancement of macrophage T-lymphocyte cooperation in concanavalin A-induced lymphocyte activation. Immunobiology 157:474

    Google Scholar 

  22. Knop J (1980) Effect of Vibrio cholerae neuraminidase on the mitogen response of T-lymphocytes. II. Modulation of the lymphocyte response to macrophage released factors by neuraminidase. Immunobiology 157:486

    Google Scholar 

  23. Knop J, Sedlacek HH, Seiler FR (1978) Stimulatory effect of Vibrio cholerae neuraminidase on the antibody response to various antigens. Immunology 34:181

    Google Scholar 

  24. Knop J, Ax W, Sedlacek HH, Seiler FR (1978) Effect of Vibrio cholerae neuraminidase on the phagocytosis of E. coli by macrophages in vivo and in vitro. Immunology 34:555

    Google Scholar 

  25. Nakamura RM, Chisari FV, Edgington TS (1975) Laboratory tests for diagnosis of autoimmune disease. In: Progress in clinical pathology. Grune and Stratton, New York, p 177

    Google Scholar 

  26. Naor D (1983) Coexistence of immunogenic and suppressogenic epitopes in tumor cells and various types of macromolecules. Cancer Immunol Immunother 16:1

    Google Scholar 

  27. Parodi AL, Misdorp W, Mialot JP, Mialot M, Hart AAM, Hurtrel M, Salomon JC (1983) Intratumoral BCG and Corynebacterium parvum therapy of canine mammary tumours before radical mastectomy. Cancer Immunol Immunother 15:172

    Google Scholar 

  28. Pernice W, Sedlacek HH (1979) Antigen-specific detection of soluble immune complexes by a solid phase specific antibody system. J Immunol Methods 28:33

    Google Scholar 

  29. Reisner EG, Flye K, Su Chung S, Amos DB (1974) The cytotoxic reactivity and sialic acid content of human lymphoid cells. Tissue Antigens 4:7

    Google Scholar 

  30. Rios A, Simmons RL (1974) Active specific immunotherapy of minimal residual tumor: Excision plus neuraminidase-treated tumor cells. Int J Cancer 13:71

    Google Scholar 

  31. Romeis B (1968) Mikroskopische Technik. Oldenbourg Verlag, München, p 339

    Google Scholar 

  32. Ronneberger H (1978) Toxicological studies with therapeutically applicable Vibrio cholerae neuraminidase. Dev Biol Stand 38:413

    Google Scholar 

  33. Ronneberger H, Johannsen R (1979) BCG sensitization of guinea pigs — an animal model for demonstrating the immunostimulating effects of various substances. Int J Immunopharmacol 1:113

    Google Scholar 

  34. Rosenberg SA, Plocinik BA, Rogentine GN (1972) “Unmasking” of human lymphoid cell heteroantigens by neuraminidase treatment. J Natl Cancer Inst 48:1271

    Google Scholar 

  35. Sanford BH (1967) An alteration in tumor host compatibility induced by neuraminidase. Transplantation 5:1273

    Google Scholar 

  36. Schermer S (1958) Blutmorphologie der Laboratoriumstiere. Johann Ambrosius, New York, p 85

    Google Scholar 

  37. Schick HJ, Zilg H (1978) Production and quality control of therapeutically applicable Vibrio cholerae neuraminidase (VCN). Dev Biol Stand 38:81

    Google Scholar 

  38. Schneider R (1970) Comparison of age, sex and incidence rates in human and canine breast cancer. Cancer 26:419

    Google Scholar 

  39. Sedlacek HH (1986) Specific tumor therapy with neuraminidase and tumor cells: Biochemical, immunological and oncological aspects (in press)

  40. Sedlacek HH, Seiler FR (1974) Demonstration of Vibrio cholerae neuraminidase (VCN) on the surface of VCN-treated cells. Behring Inst Mitt 55:254

    Google Scholar 

  41. Sedlacek HH, Seiler FR (1978) Effect of Vibrio cholerae neuraminidase on the cellular immune response in vivo. In: Proceedings of the Symposium “Immunotherapy of malignant diseases”. Schattauer, Stuttgart, p 268

    Google Scholar 

  42. Sedlacek HH, Seiler FR (1978) Immunotherapy of neoplastic diseases with neuraminidase: Contradictions, new aspects, and revised concepts. Cancer Immunol Immunother 5:153

    Google Scholar 

  43. Sedlacek HH, Seiler FR (1978) Spontaneous mammary tumors in mongrel dogs. A relevant model to demonstrate tumor therapeutical success by application of neuraminidase-treated tumor cells. Dev Biol Stand 38:399

    Google Scholar 

  44. Sedlacek HH, Meesmann H, Seiler FR (1975) Regression of spontaneous mammary tumors in dogs after injection of neuraminidase-treated tumor cells. Int J Cancer 15:409

    Google Scholar 

  45. Sedlacek HH, Dersjant H, Baudner S, Seiler FR (1976) Critical evaluation of the value of immunofluorescence methods for the demonstration of immunoglobulins on the lymphocyte surface. Behring Inst Mitt 59:38

    Google Scholar 

  46. Sedlacek HH, Seiler FR, Schwick HG (1977) Neuraminidase and tumor immunotherapy. Klin Wschr 55:199

    Google Scholar 

  47. Sedlacek HH, Weise M, Lemmer A, Seiler FR (1979) Immunotherapy of spontaneous mammary tumors in mongrel dogs with autologous tumor cells and neuraminidase. Cancer Immunol Immunother 6:47

    Google Scholar 

  48. Sedlacek HH, Weidmann E, Seiler FR (1982) Tumour immunotherapy using Vibrio cholerae neuraminidase (VCN). In: Bacteria and cancer. Academic Press, London, p 263

    Google Scholar 

  49. Seiler FR, Sedlacek HH (1978) Chessboard vaccination: A pertinent approach to immunotherapy of cancer with neuraminidase and tumor cells? Proceedings of the Symposium “Immunotherapy on malignant diseases”. Schattauer, Stuttgart, p 479

    Google Scholar 

  50. Seiler FR, Sedlacek HH (1980) BCG versus VCN: The antigenicity and the adjuvant effect of both compounds. Recent Results Cancer Res 75:53

    Google Scholar 

  51. Sethi KK, Brandis H (1973) Neuraminidase induced loss in the transplantability of murine leukaemia L 1210, induction of immunoprotection and the transfer of induced immunity to normal DBA/2 mice by serum and peritoneal cells. Br J Cancer 27:106

    Google Scholar 

  52. Simmons RL, Rios A (1971) Immunotherapy of cancer: Immunospecific rejection of tumours in recipients of neuraminidase-treated tumour cells plus BCG. Science 174:591

    Google Scholar 

  53. Simmons RL, Rios A (1973) Differential effect of neuraminidase on the immunogenicity of viral associated and private antigens of mammary carcinomas. J Immunol 111:1820

    Google Scholar 

  54. Simmons RL, Rios A (1974) Cell surface modification in the treatment of experimental cancer with neuraminidase or concanavalin A. Cancer 34:1541

    Google Scholar 

  55. Simmons RL, Rios A (1974) Immunospecific regression of methylcholanthrene fibrosarcoma with the use of neuraminidase. V. Quantitative aspects of the experimental immunotherapeutic model. Isr J Med Sci 10:925

    Google Scholar 

  56. Simmons RL, Rios A, Ray PK (1970) Mechanism of neuraminidase-induced antigen “unmasking”. Surg Forum 21:265

    Google Scholar 

  57. Simmons RL, Lipschultz ML, Rios A, Ray PK (1971) Failure of neuraminidase to unmask histocompatibility antigens on trophoblast. Nature (New Biology) 231:111

    Google Scholar 

  58. Simmons RL, Rios A, Ray PL, Lundgren G (1971) Effect of neuraminidase on growth of a 3-methylcholanthrene-induced fibrosarcoma in normal and immunosuppressed syngeneic mice. J Natl Cancer Inst 47:1087

    Google Scholar 

  59. Song CW, Levitt SH (1975) Immunotherapy with neuraminidase treated tumour cells after radiotherapy. Radiat Res 64:485

    Google Scholar 

  60. Springer GF, Desai PR (1975) Human blood group MN and precursor specificities: Structural and biological aspects. Carbohydr Res 40:183

    Google Scholar 

  61. Springer GF, Desai PR (1975) Increase in anti-T titer scores of breast-carcinoma patients following mastectomy. Naturwissenschaften 62:587

    Google Scholar 

  62. Springer GF, Desai PR, Banatwala I (1974) Blood group MN-specific substances and precursors in normal and malignant human breast tissues. Naturwissenschaften 61:457

    Google Scholar 

  63. Springer GF, Desai PR, Murthy MS, Scanlon EF (1979) Delayed-type skin hypersensitivity reaction (DTH) to Thomsen-Friedenreich (T) antigen as diagnostic test for human breast adenocarcinoma. Klin Wschr 57:961

    Google Scholar 

  64. Springer GF, Desai PR, Murthy MS, Tegtmeyer H, Scanlon EF (1979) Human carcinoma-associated precursor antigens of the blood group MN system and the host's immune responses to them. Progr Allergy 26:42

    Google Scholar 

  65. Springer GF, Desai PR, Fry WA, Goodale RL, Shearen JG, Scanlon EF (1982) Importance of breast, lung, and pancreas carcinoma cell membrane T antigen in their immunodiagnosis. In: Membranes in tumour growth. Elsevier Biomedical Press, p 575

  66. Springer GF, Murthy SM, Desai PR, Fry WA, Tegtmeyer H, Scanlon EF (1982) Patients' immune response to breast and lung carcinoma-associated Thomsen-Friedenreich (T) specificity. Klin Wschr 60:121

    Google Scholar 

  67. Springer GF, Desai PR, Fry WA, Goodale RL, Shearen JG, Scanlon EF (1983) T antigen, a tumor marker against which breast, lung, pancreas carcinoma patients mount immune responses. Cancer Detect Prev 6:111

    Google Scholar 

  68. Uhlenbruck G (1981) The Thomsen-Friedenreich (TF) receptor: an old history with new mystery. Immunol Commun 10:251

    Google Scholar 

  69. Vaith P, Uhlenbruck G (1978) The Thomsen agglutination phenomenon: a discovery revisited 50 years later. Ztschr Immunitätsforsch 154:1

    Google Scholar 

  70. Vierbuchen M, Klein PJ, Uhlenbruck G, Fischer R (1981) Hormonabhängige Lektin-Bindungsstellen. I. Histochemischer Nachweis von Lektin-Bindungsstellen und ihre hormonelle Steuerung im Brustdrüsengewebe der Ratte. In: Symposium Carcinoembryonales Antigen (CEA) und andere Tumormarker. Leonberg

  71. Warren L (1959) The thiobarbituric acid assay of sialic acids. J Biol Chem 234:1971

    Google Scholar 

  72. Wilson RE, Sonis ST, Godrick EA (1974) Neuraminidase as an adjunct in the treatment of residual systemic tumor with specific immune therapy. Behring Inst Mitt 55:334

    Google Scholar 

  73. Wunderlich M, Schiessel R, Rainer H, Rauhs R, Kovats E, Schemper M, Dittrich Ch, Micksche M, Sedlacek HH (1985) Effect of adjuvant chemo- or immunotherapy on the prognosis of colorectal cancer operated for cure. Br J Surg, Suppl.: S 107

Download references

Author information

Authors and Affiliations

  1. Research Laboratories of Behringwerke AG, D-3550, Marburg, Federal Republic of Germany

    H. H. Sedlacek, G. Hagmayer & F. R. Seiler

Authors
  1. H. H. Sedlacek
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Hagmayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. F. R. Seiler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sedlacek, H.H., Hagmayer, G. & Seiler, F.R. Tumor therapy of neoplastic diseases with tumor cells and neuraminidase. Cancer Immunol Immunother 23, 192–199 (1986). https://doi.org/10.1007/BF00205649

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00205649

Keywords

Search

Navigation